CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 64 enrolled
Drug / intervention
RSLV-132 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02660944
NCT02660944Phase 2Completed
CompareCT.gov

A Phase 2a, Double-blind, Placebo-Controlled Study of RSLV-132 in Subjects With Systemic Lupus Erythematosus (SLE)

Resolve Therapeutics·interventional·Posted Jan 21, 2016·Updated Mar 10, 2021

In Brief

A Phase 2 clinical trial evaluating RSLV-132 and Placebo for Systemic Lupus Erythematosus. Completed, enrolled 64 participants across 16 sites.

Detailed Summary

This study evaluates the impact of 13 bi-weekly intravenous infusions of RSLV-132 on the cutaneous manifestations in subjects with systemic lupus erythematosus.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSystemic Lupus Erythematosus
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedJan 21, 2016
Enrollment StartJan 3, 2016
Primary CompletionMay 28, 2020
Study CompletionAug 10, 2020
TodayJul 2, 2026
Enrollment to primary: 4.4 yearsPosted 10.4 years ago

Interventions

RSLV-132drug

RNase-Fc fusion protein

Placebodrug

Saline placebo